Number of Affected Nails Is the Primary Determinant of Efinaconazole 10% Solution Usage for Onychomycosis

February 2024 | Volume 23 | Issue 2 | 110 | Copyright © February 2024


Published online January 20, 2024

Steven R. Feldman MD PhDa, Tracey C. Vlahovic DPMb, Warren S. Joseph DPMc, C. Ralph Daniel MDd, Boni Elewski MDe, Phoebe Rich MDf, Shari R. Lipner MD PhDg

aWake Forest School of Medicine, Winston-Salem, NC 
bTemple University School of Podiatric Medicine, Philadelphia, PA 
cArizona College of Podiatric Medicine, Midwestern University, Glendale, AZ 
dUniversity of Mississippi Medical Center, Jackson, MS 
eUniversity of Alabama at Birmingham School of Medicine, Birmingham, AL 
fOregon Health and Science University, Portland, OR 
gWeill Cornell Medicine, New York, NY

DISCLOSURES

Steven R. Feldman has received research, speaking and/or consulting support from BMS, Eli Lilly and Company, GlaxoSmithKline/Stiefel, AbbVie, Janssen, Alovtech, vTv Therapeutics, Bristol-Myers Squibb, Samsung, Pfizer, Boehringer Ingelheim, Amgen, Dermavant, Arcutis, Novartis, Novan, UCB, Helsinn, Sun Pharma, Almirall, Galderma, Leo Pharma, Mylan, Celgene, Ortho Dermatologics, Menlo, Merck & Co, Qurient, Forte, Arena, Biocon, Accordant, Argenx, Sanofi, Regeneron, the National Biological Corporation, Caremark, Teladoc, Eurofins, Informa, UpToDate, and the National Psoriasis Foundation. He is the founder and part owner of Causa Research and holds stock in Sensal Health. Shari R. Lipner has served as a consultant for Ortho Dermatologics, Hoth Therapeutics, Moberg Pharmaceuticals, and BelleTorus Corporation. Tracey C Vlahovic has served as investigator and speaker for Ortho Dermatologics. Warren S. Joseph has served as a consultant and speaker for Ortho Dermatologics. C. Ralph Daniel has provided clinical research support to Ortho Dermatologics and owns stock in Medimetriks Pharmaceuticals. Boni Elewski has provided clinical research support (research funding to University) for AbbVie, Anaptys-Bio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Incyte, LEO Pharma, Lilly, Merck, Menlo, Novartis, Pfizer, Regeneron, Sun Pharma, Ortho Dermatologics, Vanda; and as consultant (received honorarium) from Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, LEO Pharma, Lilly, Menlo, Novartis, Pfizer, Sun Pharma, Ortho Dermatologics, Verrica. Phoebe Rich has received research and educational grants from AbbVie, Allergan, Anacor Pharmaceuticals, Boehringer Ingelheim, Cassiopea, Dermira, Eli Lilly, Galderma, Janssen Ortho Inc., Kadmon Corporation, LEO Pharma, Merck, Moberg Derma, Novartis, Pfizer, Ranbaxy Laboratories Limited, Sandoz, Viamet Pharmaceutical Inc., Innovation Pharmaceuticals (Cellceutix), and Cutanea Life Sciences.

ACKNOWLEDGMENT

Medical writing and editorial support were provided by Kevin Corcoran, PhD, and Jacqueline Benjamin, PhD of Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics. Ortho Dermatologics is a division of Bausch Health US, LLC.

REFERENCES

  1. LaSenna CE, Tosti A. Patient considerations in the management of toe onychomycosis - role of efinaconazole. Patient Prefer Adherence. 2015;9:887-891. 
  2. Lipner SR, Ko D. Optimizing topical therapy for onychomycosis: The importance of patient education. Cutis. 2018;102(6):389-390. 
  3. Ortho Dermatologics. [data on file]. 
  4. Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600-608. 
  5. JUBLIA (Efinaconazole) Topical Solution, 10% [package insert]. Bridgewater, NJ: Ortho Dermatologics; 2022. 

AUTHOR CORRESPONDENCE

Steven R Feldman MD PhD sfeldman@wakehealth.edu
Close Menu